Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT
· Real-Time Price · USD
23.84
0.75 (3.25%)
At close: May 16, 2025, 3:59 PM
23.55
-1.24%
Pre-market: May 19, 2025, 04:11 AM EDT
3.25% (1D)
Bid | 23.17 |
Market Cap | 17.59B |
Revenue (ttm) | n/a |
Net Income (ttm) | -240.75M |
EPS (ttm) | -0.34 |
PE Ratio (ttm) | -70.13 |
Forward PE | -47.04 |
Analyst | Buy |
Ask | 23.88 |
Volume | 1,341,660 |
Avg. Volume (20D) | 4,065,237 |
Open | 23.42 |
Previous Close | 23.09 |
Day's Range | 23.05 - 23.94 |
52-Week Range | 2.10 - 36.91 |
Beta | -0.95 |
About SMMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SMMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SMMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-36.05%
Summit Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
3 weeks ago
+21.5%
Summit Therapeutics shares are trading higher after the company provided updates on its Phase 3 trial of Ivonescimab and announced it met its primary endpoint.